Bioventus (NASDAQ:BVS) Cut to Buy at Wall Street Zen

Wall Street Zen cut shares of Bioventus (NASDAQ:BVS) from a strong-buy rating to a buy rating in a report published on Saturday morning,Wall Street Zen reports.

Several other brokerages have also issued reports on BVS. Barrington Research set a $18.00 price target on Bioventus in a research note on Thursday, August 6th. Weiss Ratings lowered Bioventus from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Wednesday, November 4th. Craig Hallum reissued a “buy” rating and set a $18.00 price objective on shares of Bioventus in a report on Thursday, August 6th. Canaccord Genuity Group decreased their price objective on Bioventus from $19.00 to $18.00 and set a “buy” rating on the stock in a report on Tuesday, November 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $15.00 target price on shares of Bioventus in a research report on Monday, August 17th. Five investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $16.60.

Bioventus Stock Performance

Bioventus stock opened at $11.02 on Friday. The firm’s fifty day moving average price is $13.38 and its 200-day moving average price is $10.98. The company has a debt-to-equity ratio of 0.72, a quick ratio of 1.17 and a current ratio of 1.68. The stock has a market cap of $926.67 million, a P/E ratio of 14.64, a price-to-earnings-growth ratio of 1.46 and a beta of 0.66. Bioventus has a fifty-two week low of $6.47 and a fifty-two week high of $15.89.

Bioventus (NASDAQ:BVS) last posted its quarterly earnings data on Monday, November 2nd. The company reported $0.17 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.17. Bioventus had a net margin of 9.78% and a return on equity of 26.31%. The company had revenue of $142.44 million during the quarter. On average, equities research analysts expect that Bioventus will post 0.78 earnings per share for the current fiscal year.

Institutional Trading of Bioventus

Several institutional investors have recently added to or reduced their stakes in BVS. Russell Investments Group Ltd. grew its position in Bioventus by 692.5% during the 3rd quarter. Russell Investments Group Ltd. now owns 145,943 shares of the company’s stock worth $1,989,000 after acquiring an additional 127,528 shares during the last quarter. Ritholtz Wealth Management bought a new stake in Bioventus in the third quarter valued at approximately $320,000. Allspring Global Investments Holdings LLC lifted its position in Bioventus by 4.1% in the third quarter. Allspring Global Investments Holdings LLC now owns 85,874 shares of the company’s stock valued at $1,170,000 after purchasing an additional 3,367 shares during the last quarter. Covestor Ltd boosted its stake in shares of Bioventus by 25.6% during the third quarter. Covestor Ltd now owns 5,808 shares of the company’s stock valued at $79,000 after purchasing an additional 1,182 shares during the period. Finally, Signaturefd LLC boosted its stake in shares of Bioventus by 2,809.1% during the third quarter. Signaturefd LLC now owns 1,920 shares of the company’s stock valued at $26,000 after purchasing an additional 1,854 shares during the period. 62.94% of the stock is currently owned by hedge funds and other institutional investors.

Bioventus Company Profile

Bioventus Inc is a medical device and biologics company focused on developing and commercializing products that support bone healing, joint health and surgical recovery. Its portfolio is designed to help healthcare professionals treat musculoskeletal conditions and improve patient outcomes through noninvasive therapies, injectable products and biologic solutions.

The company’s offerings include bone stimulation systems such as EXOGEN, which is used to support fracture healing, as well as injectable osteoarthritis treatments including DUROLANE and GELSYN-3.